Société de Pneumologie de Langue Française (SPLF)
This sponsor has funded 1 studies across 1 countries.
| EU PAS ID | Status | Title | Protocol uploaded | Results uploaded |
|---|---|---|---|---|
| 105374 | Ongoing | Anti-IL-5/5R versus anti-IL4R switching strategies for uncontrolled severe asthma treated by anti-IL5/5R : A target trial emulation (RAMSES-Switch) | No | No |
PAS by Risk Management Plan (RMP) requirement
Société de Pneumologie de Langue Française (SPLF)
The RMP for a medical product outlines strategies to identify, assess, and mitigate risks, including PAS for further evaluation.
Category 1 studies are imposed as condition of marketing authorisation.
Category 2 studies are imposed as specific obligation of marketing authorisation.
Category 3 studies are required under other circumstances.
PAS by study status
Société de Pneumologie de Langue Française (SPLF)
The study status is defined according to the timeline dates specified.
Planned studies have not collected any data yet.
Ongoing studies collect data and should publish protocols as soon as possible.
Finalised studies should publish results in the first two weeks after finalisation.
Countries
Société de Pneumologie de Langue Française (SPLF)
1 Study countries specified are the following:
- France